Can E6E7 Alter The Competitive Balance In The Crowded HPV Test Market?
Executive Summary
The October introduction of Gen-Probe’s new cervical cancer screening test may up the stakes in the battle over market share in testing for HPV, the cause of cervical cancer. That’s good news for several companies. One is OncoHealth, which is developing a low-cost protein-based test for direct measurement of E6E7, two important oncoproteins associated with HPV progression to cancer that are a part of Gen-Probe’s new test panel.
You may also be interested in...
NCI-Funded Device Start-Ups Offer Game-Changing Technologies
At the NCI SBIR 2012 Investor Forum, a select group of SBIR grant-funded emerging cancer device companies presented promising next-generation technologies poised to dramatically impact survival from a variety of cancers, including deadly lung, liver, and esophageal malignancies.
Medical Device Market & Industry Briefs, May 2012
Brief summaries of recent medtech market and industry developments. This month we cover Hologic’s acquisition of Gen-Probe, highlights from Heart Rhythm 2012 and a wrap-up of life sciences venture capital funding for Q1 2012.
Hologic Grabs Gen-Probe
Women’s health-focused Hologic is buying molecular diagnostics provider Gen-Probe for $3.7 billion in cash. Adding Gen-Probe’s automated instrument platforms gives Hologic critical mass in the molecular diagnostics market while allowing it to maintain its core focus on women’s health. Hologic’s international direct sales force and dealer network can further drive adoption of US-oriented Gen-Probe’s tests in both developed and emerging markets. It also gives Gen-Probe a much greater capability for selling to physicians as well as labs, filling a second significant gap in Gen-Probe’s marketing.